122 results about "Corneal epithelium" patented technology

A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements, and a growth factor(s) which maintains and enhances the preservation of eye tissues, including human corneal, retinal and corneal epithelial tissues at low to physiological temperatures (2 DEG C. to 38 DEG C.). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s), a deturgescent agent(s), an energy source(s), a buffer system(s), an antioxidant(s), membrane stabilizing agents, an antibiotic(s) and/or antimycotic agent(s), ATP or energy precursors, nutrient cell supplements, coenzymes and enzyme supplements, nucleotide precursors, hormonal supplements, non-essential amino acids, trace minerals, trace elements and a growth factor(s).

A method for stabilizing collagenous eye tissues by nitrite and nitroalcohol treatment. The topical stiffening agent contains sodium nitrite or a nitroalcohol in a buffered balanced salt solution and can be applied to the surface of the eye on a daily basis for a prolonged period. Application of the solution results in progressive stabilization of the corneal and scleral tissues through non-enzymatic cross-linking of collagen fibers. The compounds can penetrate into the corneal stroma without the need to remove the corneal epithelium. In addition, ultraviolet light is not needed to activate the cross-linking process. The resulting stabilization of corneal and scleral tissues can prevent future alterations in corneal curvature and has utility in diseases such as keratoconus, keratectasia, progressive myopia, and glaucoma.

The invention relates to hydrogel for intelligent desorption of a cell sheet layer and an application of the hydrogel. The hydrogel is formed by dissolving functional monomers M1, chemical or physical crosslinking agents M2 and water-solubility biomacromolecules M3 in solvents 4 and adopting an oxidation reduction initiating system for free radical polymerization, and the mass percentages of M1, M2, M3 and M4 are respectively 5 to 10 percent, 2 to 10 percent, 1 to 15 percent and 75 to 92 percent. The hydrogel has excellent temperature or pH value response characteristics and biocompatibility, and the fast multiplication and desorption of cells can be effectively promoted. The cell sheet layer formed after the desorption maintains the complete cell epimatrix, and the biological function damage of the cells caused by an enzyme hydrolysis method and the cell damage caused by degradation ingredients of support frame materials are avoided. The cell sheet layer after the intelligent desorption by the hydrogel can be used for treating and repairing relevant tissues and organs of skin, corneal epithelium and parodontium ligament.

The invention discloses a method and application for preparing a tissue engineering corneal carrier stent by utilizing fresh porcine cornea. The method comprises the following steps: cutting a fresh porcine cornea for swelling, repeatedly freeze thawing and breaking cells, removing residual nucleic acid substances through DNA-RNA enzyme treatment, cross-linking, airing, and finally performing irradiation sterilization through ionization rays, thereby obtaining the product. The method is applied to carrier stents of tissue engineering corneal epithelium, stroma, endothelium, front board layer half cornea, rear board layer half cornea and full-layer board layer half cornea, so that the requirement on batch production of tissue engineering corneas is met. The carrier stent serves as a substitute of human corneal stroma to be used for clinical transplant and treatment of un-accumulated whole layer keratohelcosis. The method is applied to large-scale production and clinical popularization and application. The prepared carrier stent has the characteristics of high transparency, dense structure, high mechanical property, high biocompatibility with human corneal seed cells and the like. Therefore, the method is suitable for batch production, so that the requirements on lots of carrier stents for tissue engineering corneas are met.

A drive tool for optical surgery includes a handpiece containing a traverse motor and an oscillating motor, wherein the oscillating motor is axially driven through the handpiece by the traverse motor. A head assembly including a suction ring is mounted to the handpiece, and a separator drive assembly is positioned therein for advancement imparted by the traverse motor and oscillation imparted by the oscillating motor.

The invention relates to a reconstruction method of tissue engineering human corneal epithelium. The method comprises the following steps of: adopting a DMEM/F12 culture medium containing 20% calf serum to carry out the in vitro culture on human corneal epithelium cells to a logarithmic growth phase, and adopting trypsin and a trypsin-EDTA digestion method to obtain a digestive amniotic carrier bracket of which the epithelium is completely removed; and after the digestive amniotic carrier bracket of which the epithelium is removed is flatly laid in a plug-in Petri dish and is firmly and pasted in a drying way, inoculating the human corneal epithelium cells at the logarithmic growth phase suspended in the DMEM/F12 culture medium containing IV type collagen and 20% calf serum to the plug-inPetri dish flatly laid with the digestive amniotic carrier bracket of which the epithelium is removed, and carrying out the in vitro reconstruction on the tissue engineering human corneal epithelium by a gas-liquid interface culture method. The invention has scientific and reasonable process, the reconstructed tissue engineering human corneal epithelium can be used for mass production, a lot of demands of vast blind patients with corneal epithelium diseases for the tissue engineering human corneal epithelium in clinical corneal transplantation treatment can be met, and the costs of the in vitro reconstruction and clinical treatment of the tissue engineering human corneal epithelium are low.

Methods of increasing the permeability of corneal epithelium to facilitate the diffusion of agents into the collagen fibrillar network of the stroma are provided. Used in combination, these methods open the epithelium to facilitate diffusion of stabilization molecules into the stroma and dissociate bridging molecules from stromal collagen fibers, thereby priming the collagen fibrillar network for restabilization by stabilization molecules. These methods can be used to increase the effectiveness and longevity of non-invasive corneal reshaping, such as orthokeratology, for correcting myopia, hyperopia and astigmatism.

The invention discloses eye drops with the function of relieving the symptom of xeroma, which are characterized by comprising a recombinant human keratinocyte growth factor-2, a protein protective agent, a thickening agent, an osmotic pressure regulator and a proper buffer system in a certain proportion; the invention also discloses a preparation method of the eye drops. Pharmacological experiments show that the eye drops can delay the rupture time of the lacrimal film, maintain the integrity of the ocular barrier, restore the ocular immunological network and relieve the symptom of the xeroma by restoring the corneal epithelium.

The invention provides a method and assay kits for detecting keratoconus, including sub clinical keratoconus, in a specimen. The method comprises assaying a specimen of corneal epithelium for the presence of an expression product of the AQP5 gene. The invention further provides a novel gene, KC6, that exhibits cornea-specific expression, as well as KC6-related molecules.

An agent for treatment of dry eye comprising a combination of a P2Y₂ receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration, which agent has a dosage form of an ophthalmic agent, can promote the secretion of tear remarkably and can improve corneal epithelial disorders remarkably, and is therefore expected to be a novel agent for treatment of dry eye.

The invention relates to a cell population comprising minimal volume of orbital fat-derived stem cells (OFSCs) and its isolation, purification, characterization and application. The OFSCs of the invention are capable of multilineage development and express at least CD90 and CD 105 but not hematopoietic and epithelial markers. The OFSCs have colony formation ability and multi-lineage differentiation ability. They possess at least osteogenic, chondrogenic and adipogenic differentiation capacity; besides mesodermal tri-linage differentiation, the OFSCs have corneal epithelial differentiation potential. Taking together, orbital fat tissues are a novel source for multi-potent stem cells which possess multiple therapeutic potential. Therefore, the OFSCs can be used in cell therapy and tissue engineering.

The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RARγ agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis. The therapeutic agent is also useful as a therapeutic agent for corneal scarring and conjunctival scarring both associated with keratoconjunctive disorders.

The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

A porous nanometer carbon-polyvinyl alcohol hydrogel artificial cornea, which is used for patients of cornea diaphaneity descent and cornea blind caused by eye tissue diseases, consisting of an optical part and a supporting part, the optical part being made from transparent polyvinyl alcohol hydrogel, and the supporting part being made from black nanometer carbon materials. The optical part is provided with an upper and a lower surface, the supporting part enwraps the optical part, combines tightly with human cornea tissues, and is embedded in the optical part. The materials of the optical part protrude on the top and the bottom and overtops the supporting part at the joint of the two parts, and forms a trapezoid right-angle structure. The invention overcomes the shortcomings of existing techniques, and is capable of watertightness engomphosis with host cornea, preventing infection, degrowth of corneal epitheliums, antagonizing intra-ocular pressure, and preventing the forming of the back fibrous membrane of cornea. The artificial cornea has advantages of tenderness, good elasticity, certain tensile strength, convenience in surgical operation, and maximum decrease of complicating diseases.

An apparatus and a method for removing epithelium from the cornea include a fluid agent for facilitating de-epithelialization of the cornea. A disc includes a biocompatible material operable for covering a predetermined zone of a cornea. The disc is hydrated by the fluid agent, wherein the hydrated disc is pliable for conforming to a surface of the cornea. An application of the hydrated disc to the cornea substantially constrains the fluid agent to the determined zone and softens a corneal epithelium enabling delamination of the epithelium from an underlying stroma.

The invention relates to the field of medicine and particularly relates to sodium hyaluronate eye drops and preparation method thereof. Every 100 ml of the sodium hyaluronate eye drops comprise the following components: 80 to 150 mg of sodium hyaluronate, 130 to 200 mg of boric acid, 10 to 20 mg of borax, 8 to 15 mg of edetate disodium, 80 to 160 mg of 6-amino caproic acid, 80 to 160 mg of mannitol, 600 to 800 mg of sodium chloride, 3 to 10 mg of benzalkonium chloride, and 8 to 15 mg of borneo camphor, wherein 100 ml of water for injection is added, and the pH value is regulated to 6.0 to 7.8. The eye drops provided by the invention can play the role of promoting healing of injuries of corneal epithelium, can prolong the break-up time remarkably and can better improve the symptoms of xerophthalmia. Meanwhile, the sodium hyaluronate eye drops have good stability at ambient temperature, and all figures are similar, which indicates that the preparation technology is steady and practicable; and if the eye drops are used within the available period, the indexes of HA-Na are all within the quality control range.

This invention provides experimental animals suffering corneal epithelial damages, such as dry eye, and methods of using the same to assay a variety of compounds for evaluating the therapeutic effect on the disease, and medicine selected using the method, wherein the corneal epithelial damage is induced by the steps of: using a water-absorbing material having a physical state selected from powder, solution, gel, jelly and tablet, and contacting the absorbing materials with the ocular cornea to generate a difference in osmotic pressure between the inside and outside of ocular corneal epithelium cells.